Clerk of the House of Representatives
Legislative Resource Center
B-106 Cannon Building
Washington, DC 20515

Secretary of the Senate Office of Public Records 232 Hart Building Washington, DC 20510 SECRETARY OF THE SENATE

05 AUG 17 AN 10: 45

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required To Complete This Page

		<u></u>	d -	
1. Registrant Name				
King & Spalding LLP	***************************************			
2. Address Check if different than previously repo	rted			
1700 Pennsylvania Avenue, NW, Washir	ngton, DC 200	006		
3. Principal Place of Business (if different from line 2)			!	
City:	State/Zip (or Country)			
•	Telephone E-mail (optional)		5. Senate ID#	
Mark H. Smith (2	(202) 737-0500			
7. Client Name			6. House ID#	
National Patient Advocate Foundation			30750	
INCOME OR EXPENSES - Cor	nplete Either	41955***********************************	41	
12. Lobbying Firms		13. Organizations		
INCOME relating to lobbying activities for the period was:	is reporting	EXPENSES relating to lobbying acti period were:	vities for this repo	
Less than \$10,000 ·		Less than \$10,000 🗖		
\$10,000 or more Income (nearest \$20,000) Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).	200 00	\$10,000 or more □ ⇒ \$		
		Expenses (nearest \$20,00 14. REPORTING METHOD. Check box to indicate		
	accounting method. See instructions for description of			
	Method A. Reporting amounts using LDA definit			
	Method B. Reporting amounts under section 603. Internal Revenue Code			
		Method C. Reporting amounts under section 162 Internal Revenue Code		
Signature Diametrical	nixe			

LD-2 (REV. 6/98)

۲

Registrant Name	King & Spalding LLP	Client Name	National Patient Advocate Foundation	
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the reengaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, information as requested. Attach additional page(s) as needed.				
15. General issue area	a code MMM (one	per page)		
P.L. 108-173—Medicare Prescription Drug Improvement and Modernization Act of 2003 Medicare coverage of oral anticancer therapeutic products H.R.1812 and S.898 Patient Navigator, Outreach and Chronic Disease Prevention Act Appropriations				
17. House(s) of Congress and Federal agencies contacted US Senate US House of Representatives Centers for Medicare and Medicaid Services 18. Name of each individual who acted as a lobbyist in this issue area				
Mark H. Smith	Name		Covered Official Position (if applicable)	
Andrew L. Woods	eign entity in the specific iss		ve 🔽 Check if None	
Signature	Jara H Sa	ul	Date 8/9/05.	

Printed Name and Title

Form LD-2 (Rev.6/98)

Page __